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Effects of high dialysate calcium concentration on bone remod-
elling, serum biochemistry, and parathyroid hormone in patients with
renal osteodystrophy. The influence of a dialysate calcium concen-
tration of 8.0 mg/lOO ml (treatment period 2) vs. 7.0 mg/l0O ml
(treatment period I) on plasma calcium, phosphorus, serum im-
munoreactive parathyroid hormone (iPTH), bone histology, in-
testinal calcium absorption, and calcium transfer across the
dialysis membrane was investigated in six patients with renal os-
teodystrophy undergoing intermittent hemodialysis. During the
periods I and 2, the plasma calcium changes before and after
dialysis were not significantly different. A significant increase in
mean postdialysis plasma calcium level was observed during both
periods when compared to mean predialysis level. A significant,
inverse relation was found between predialysis plasma calcium and
the increase in plasma calcium during hemodialysis runs. Calcium
transfer across the dialysis membrane and fractional intestinal
absorption of calcium in the postdialysis state were determined in
four out of the six patients. During period 2, calcium transfer was
higher in all four patients but intestinal calcium absorption was
moderately higher only in one and strikingly lower in the remain-
ing three patients when compared to period 1. Although brought
up to 8.0 mg/l00 ml, this higher dialysate calcium significantly
decreased the level of serum iPTH only in one Out of the six
patients; in this patient, osteoclast count, active resorption surface,
and periosteocytic osteolysis decreased. In a second patient, al-
though the level of serum iPTH seemed to decrease markedly,
osteoclastic and osteocytic resorption did not change. In the re-
maining four patients, the level of serum iPTH was unchanged and
bone resorption parameters were found unchanged or aggravated.
It is concluded that providing additional calcium (using a dialysate
calcium concentration of 8.0 mg/l0O ml), the goal of which was to
decrease secondary hyperparathyroidism, proved to be successful
only in one patient and failed to do so in the five others. Secondary
hyperparathyroidism was even found aggravated in three of them.
Thus, the use of a dialysate calcium concentration of 8.0 mg/lOO
ml did not result in any advantage over that of 7.0 mg/lOO ml in
five out of six patients studied.
Effets d'une concentration calcique élevée du bain de dialyse sur le
remaniement osseux, les paramètres biologiques seriques et Ia para-
thormone des hemodialyses atteints d'ostéodystrophie rénale. L'in-
fluence de Ia concentration en calcium du bain de dialyse sur
les paramétres biologiques sériques, Ia parathormone immuno-
reactive (iPTH), l'histologie osseuse, l'absorption digestive du
calcium et le transfert du calcium a travers Ia membrane de
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dialyse a été étudiée chez six hemodialysés chroniques. Les effets
d'une concentration en calcium du dialysat de 70 mg/litre
(période de traitement I) ont été compares a ceux d'une concentra-
tion de 80 mg/litre (période de traitement 2), chaque période
thérapeutique ayant une durée de six mois. Une augmentation
significative du taux moyen du calcium plasmatique mesuré après
les seances de dialyse, par rapport a Ia concentration mesurée
avant dialyse, a été observée dans les deux groupes ; dIe avait
une amplitude comparable dans les deux groupes. Une relation
inverse et significative a été trouvée entre le taux du calcium
plasmatique avant dialyse et le degre de l'augmentation de Ia
calcémie sous l'effet de chaque dialyse. Le transfert trans-
membranaire du calcium a été étudié chez quatre malades: il
a augmente chez tous au cours de Ia période 2. En revanche,
l'absorption intestinale fractionnelle du calcium, mesurée chez
ces quatre malades dans les 12 hr suivant une.dialyse, a diminué
chez trois d'entre eux au cours de Ia période 2 par rapport
a l'absorption fractionnelle observée au cours de Ia période 1. La
concentration plus élevée du dialysat en calcium n'a entraIné une
baisse significative du taux de l'iPTH sérique que chez l'un des six
malades ; chez ce malade, le nombre d'ostéoclastes, Ia surface de
resorption active et l'ostéolyse périostéocytaire ont diminué. Par
contre, ces trois paramètres de Ia resorption osseuse étaient, soit
inchanges, soit aggravés chez les cinq autres malades alors que les
taux de l'iPTH sérique semblaient diminuer modérément chez
quatre d'entre eux au cours de Ia période 2. Cette diminution était
cependant dans les limites des variations spontanées des taux de
l'iPTH sérique. Les auteurs concluent que l'élévation de Ia teneur
en calcium des bains de dialyse a 80 mg/litre ne procure un
avantage par rapport a Ia concentration usuelle de 7,0 mg/litre que
chez un malade sur six. Elle semble ne pas influencer
l'hyperparathyroidie secondaire chez deux malades et I'aggraver
chez les trois autres. Tout se passe comme si Ia teneur élevée en
calcium des bains de dialyse était a même de stimuler l'effet de Ia
parathormone sur Ia resorption ostéoclastique et sur l'ostéolyse
ostéocytaire de certains malades.
The incidence and degree of renal osteodystrophy
in patients undergoing chronic hemodialysis have
been shown to depend partly on dialysate calcium
concentration [1]. The use of a dialysate calcium
concentration of 5.0 mg/l00 ml was associated with a
loss of calcium from the patient into the dialysate
[2—4] and aggravated uremic bone disease [1, 5].
Dialysis against a calcium concentration of 6.0 to 7.4
mg/ml still resulted in higher rates of bone resorption
than normal [6].
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Dialysis using a dialysate calcium concentration of
8.0 mg/100 ml has been reported to be more ade-
quate than dialysis against a calcium concentration of
6.0 mg/l00 ml [7, 8]. The use of a dialysate calcium
of 8.0 mg/lOO ml, however, may induce soft tissue
calcification [9] and be associated with troubles such
as gastrointestinal symptoms [10], cardiac ar-
rhythmias [7], hypertension [11], persistent hypercal-
cemia [11], and pruritus [7].
For the present study, we have selected six patients
in whom the predialysis plasma phosphorus concen-
trations were maintained constantly below 4.5
mg/lOO ml before the onset of study, since the con-
trol of plasma phosphorus in chronically hemo-
dialyzed patients has been stressed as an important
factor in the prophylaxis of secondary hyperparathy-
roidism and consequently osteitis fibrosa [12].
The purpose of this study was to investigate pos-
sible advantages of a dialysate calcium concentration
of 8.0 over a dialysate calcium concentration of 7.0
mg/IOU ml in the treatment of renal osteodystrophy
due to chronic renal failure.
Methods
Six patients on hemodialysis were selected for the
study on the basis of 1) an initially well controlled
plasma phosphorus concentration (< 4.5 mg/100
ml); 2) full ambulation and absence of previous pro-
longed periods of immobilization; 3) absence of ste-
roid, androgen, thyroid, or vitamin D therapy; 4)
willingness to cooperate in the study. Clinical details
and the dialysis schedule are shown in Table 1.
The patients were first dialyzed against a dialysate
calcium concentration of 7.0 mg/100 ml for six
months (period 1) and then against a dialysate cal-
cium concentration of 8.0 mg/100 ml for at least
another six months (period 2). However, patients 5
and 6 were dialyzed for 8½ to 14 months until a
second bone biopsy was performed. The technique
of hemodialysis (plate kidneys with a single-pass-
dialysate supply, 20 or 30 hr per week) and the com-
position of the dialysate were identical during the two
periods with the exception of the calcium and chlo-
ride concentrations. The diet and drug therapy re-
mained unchanged during the two periods. Samples
obtained from the mixed dialysate entering the dialy-
zer were analyzed repeatedly for the concentration of
calcium, sodium, and potassium.
All the patients presented with renal as-
teodystrophy, as estimated by clinical and radio-
logical data, serum immunoreactive parathyroid
hormone (iPTH) levels, and histological criteria [13]
(Tables 2 and 3). Secondary hyperparathyroidism,
i.e., increased resorption surface, osteoclast count
and/or periosteocytic osteolysis, was present in all.
Osteomalacia, i.e., increased osteoid volume and sur-
face and reduced calcification front, was moderate in
two cases (patients 3 and 4) and more marked in the
four others.
Plasma calcium and phosphorus concentrations
were measured with an analyzer (Technicon Auto
Analyzer R, SMA-12/60); serum alkaline phospha-
tase activity was determined by the method of King
Armstrong (normal,  10 KAU). Predialysis serum
iPTH levels were measured during the last month of
each period in the six patients (2 evaluations) and
repeatedly in patients 5 and 6 (4 determinations in
each period). Parathyroid hormone levels were mea-
sured by radioimmunoassay via the method of Ar-
naud, Tsao, and Littledike [14] using a C-terminal
antibody (OP 1 M). The results were expressed in
microliter of a human standard serum (equivalent)
(normal, 0 to 40tl Eq/mi).
As in four out of the six patients studied (patients 1
through 4) only two measurements of serum iPTH
were done at the end of each treatment period, a
statistical analysis of iPTH changes observed in the
individual patient could not be carried out. There-
Table 1. Clinical data.
Length of
Residual time on
Patient Age Body wt renal dialysis, Hemodialysis
no. yr Sex kg Diagnosis function months hr/week
1 29 male 49 Chronic glomerulo-
nephritis
Anephric state 30 30
2 21 male 58 Chronic pyelo-
nephritis
Creatinine clearance
1.0 mI/mm
33 30
3 42 male 66 Chronic glomerulo-
nephritis
Anuric state 41 30
4 53 female 57 Polycystic disease Anuric state 44 20
5 40 male 57 Polycystic disease Anuric state 84 20
6 46 female 51 Chronic pyelo-
nephritis
Creatinine clearance
1.5 mI/mm
42 20
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Table 2. Evidence of renal osteodystrophy
Osteoclastic
X-ray findings Alkaline Serum resorption Calcification
Patient Clinical Bone phosphatase iPTH surface°, % of front2, % of
no. symptoms Cysts resorption KA U iI Eq/mi total surface os/coid surface
Normal — — .— 4 to 10 0to40 0.59
0 0
0 0
0 0
4 0 0 +
0
0 0 ++ 11.5 960 3.0 33.8
"Measuring the excess of resorption induced by secondary hyperparathyroidism.
2Measuring the defect of mineralization observed in all categories of osteomalacia.
= mild, + = moderate, and ++ = severe subperiosteal bone resorption.
"Mean so.
fore, to be able to interpret the observed changes in study period. The bone specimens were processed
serum iPTH, we referred to serum iPTH values ob- undecalcified, as described elsewhere [13]. For statis-
tamed in eight similar patients who had repeated tical evaluation of the observed changes, 40 to 60 thin
determinations at approximately every two weeks sections (5 to 6i) were obtained from both sides of
during a 12 week period. During this period their the bone cylinder and stained with toluidine blue.
therapeutic management was unchanged. This al- Unstained l0z thick sections were used for measuring
lowed us to evaluate the spontaneous variations of (under ultraviolet light) the extent of tetracycline la-
serum iPTH levels in these patients. The results are belling (15 mg/kg of body wt, administered orally 40
given in Table 4. Spontaneous variations were not of to 48 hr prior to the biopsy). Three to four sections
the same magnitude in all patients. Patients with high were selected (the first, the tenth, the 20th, and the
mean serum iPTH levels (from 726 to l946tl Eq/mI) 30th) from each side of the cylinder, i.e., a total
had maximum variations between 11 and 18% of the number of six to eight sections were measured and
mean, while patients with moderately to mildly ele- the means + SEM were calculated for each parameter
vated levels (from 59 to 3l2tl Eq/ml) had much evaluated.
gre1ter percentage variations: 22 to 28% of the mean. Using an integrating eye piece (Zeiss, N° 2), active
Bone histology. A bone specimen was obtained resorption surface, active osteoblastic surface, and
from the pelvis [15] during the last month of each total osteoid surface were recorded and expressed as
Table 3. Quantitative histology of the pelvis from the six patients when on I) dialysate calcium concentration of 7.0 mg/l00 ml,
and 2) dialysate calcium concentration of 8.0 mg/l00 ml (mean values [± SEMI are indicated)
Absolute vol. Osteoelastic Osteoclast Osteocytic Osteoblastic Osteoid Calcification
of cancell. resorpt. surf, count osteolysis surface surface Osteoid vol. front
Patient bone % total permm2 of % total no. % total % total % abs. vol. % of os/cold
no. % tot. vol. surface section of lacunae surface surface of bone surface
Normals
(age-matched) 19.7 + 450 0.59 + 0.17° 0.37 0.07° 3.9 ÷ 0.6° 4.9 + 1.4° 14.8 + 3.6° 4.1 + 1.1° 63.3 + 450
I. 3/5/73 45.5 1.5 2.45 0.5 0.39 + 0.16 not 4.2 0.5 31.4 3.2 15.5 0.9 62.8 5.0
2. 25/10/73 42.2 2.22 2.1 + 1.72 0.35 + 021b evaluated 3.4 1.6" 43.4 + 10.7" 19 3.0" 59.4 + 3.2°
2 I. 15/3/73 39.2 1.9 4.9 + 0.7 1.65 + 0.13 11.3 + 1.0 6.5 0.3 25.6 5.1 10.2 1.8 58.3 + 4.02. 8/11/73 41.8 1,32 3.37 ÷ 0.6" 0.83 + 0.1" 7.9 0.4" 5.2 + 1.5" 37.7 5.7" 10.6 + 1.32 56.9 3.9"
I. 8/3/73 39.8 3.6 1.45 + 1 0.21 + 0.14 9.1 + 0.9 2.9 + 0.9 18.5 4.1 7.9 1.7 43.8 + 2.7
2. 17/10/73 43.2 28" 1.79 + 062 0.23 + 0,082 8.4 + 1.32 2.7 + 1.32 20.9 42b 6.8 0.92 56.6 6.82
I. 8/3/73 46.6 + 0.6 1.28 + 0.12 0.38 0.11 not 2.1 0.7 12.4 1.5 5.0 0.7 48.3 4.0
2. 18/10/73 31.9 + 4.2° 2.04 + 0.26" 0.54 + 0.07c evaluated 1.9 0.4" 17.1 + 3.3" 7.6 1.3" 44,8 50"
1. 19/3/71 21.3 + 0.8 3.1 0.1 2.4 + 0.3 8.4 0.9 24.2 + 1.8 60.5 + 3.2 23.5 + 2.5 39 2.3
2. 10/5/72 26.4 2.7" 3.9 + 0.3° 2.8 + 0.05° 11.4 + 1.4° 20.6 + 3.3" 56.3 + 0.6" 20.6 + 0.8" 38.7 4.3"
I. 6/1/71 18.3 + 1.3 3 0.15 1.2 + 0.14 6.4 0.7 9.6 1.6 32.4 2.9 11.9 1.9 33.8 3.7
2. 28/9/71 19.1 2.7" 3.4 0.15° 1.9 + 0.01" 8.1 + 1.5° 13.2 + 2.9" 30.7 1" 8.9 + 0.3" 38.7 3.8"
a± Iso. °P<O.05.
°P=NS. "p<ool
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a percentage of the total cancellous bone surface.
Calcification front, labelled with tetracycline, was ex-
pressed as a percentage of the osteoid surface. Abso-
lute volume of cancellous bone and osteoid volume
were measured by using the integrating eye piece
(Zeiss, N° 1). Osteoclast count was expressed per
mm2 of bone section and periosteocytic osteolysis, as
a percent of the total number of osteocytic lacunae
found both in cortical or cancellous tissue. (Normal
age-matched values 1 SD are indicated in Table 3.)
Intestinal fractional absorption of calcium was per-
formed during the last month of each period in
patients I through 4, ten to twelve hours after a dialy-
sis session, according to the method of Chanard et al
[16].
The calcium transfer across the dialysis membrane
was determined for one dialysis session during the
last month of each period in patients 1 through 4,
using the method of total recovery of the calcium
entering the dialyzer.
Roentgenographic survey of the skeleton was done
every three months.
Data were evaluated statistically using Student's
test for paired values.
Results
Table -5 shows the mean plasma calcium and phos-
phorus concentrations of the last three months of
periods 1 and 2 (dialysate calcium concentration: 7.0
and 8.0 mg/100 ml, respectively) of the individual
patients determined before (Cai ; P1) and after (CaF
PF) hemodialysis runs. The increase in mean (± SEM)
plasma calcium concentration from a predialysis
value of 9.49 + 0.18 to a mean postdialysis value of
10.96 0.16 mg/lOO ml (period 1) and from 9.58
0.25 to 11.40 0.15 mg/lOO ml (period 2)was highly
significant (P < 0.001, for both periods). No signifi-
cant difference was found between the mean values of
predialysis plasma calcium concentration of periods I
and 2. The difference between post- and predialysis
values of mean (± SEM) plasma calcium concentra-
tion ( plasma [calcium]) of period 2 was not signifi-
cantly different (P> 0.2) from plasma [calcium] of
period 1 (1.82 0.27 vs. 1.47 0.16 mg/100 ml).
TableS. Mean (± SEM) plasma calcium and phosphorous concentration values before (Ca1, P1) and after (CaF, PF) hemodialysis runs during
treatment period 1 and 2 (dialysate calcium concentration of 7.0 and 8.0 mg/I00 ml, respectively)
Patient
no.
Dialysate
calcium
Plasma level
7.Omg/lOOmI 8.Omg/lOOmI 7.Omg/lOOmI 8.Omg/lOOmI
Ca1 CaF Ca1 CaF P1 PF P1 P
1
2
9.43 + 0.07 11.46 0.13
(N= 12) (N= 8)
10.04 0.10 11.40
9.28 0.09 11.27 0.13(N = I) (N= 3)
9.49 0.07 10.78 + 0.20
3.76 0.19 2.98 + 0.23
(N= II) (N= 4)
3.58 + 0.33 3.10 0.50
1.96 + 0,20 1.60
(N= 8) (N = I)
4.36 + 0.53 3.33 0.32
3
(N = 7) (N = II)
9.18 0.11 10.80 0.13
(N = 12) (N 5)
(N 13) (N = 5)
9.60 + 0.04 11.63 0.35(N 13) (N = 5)
(N = 9) (N = 2)
2.52 0.17 2.94 0.17
(N = ii) (N = 5)
(N = 5) (N = 4)
2.87 + 0.21 3.48 + 0.30
(N = 13) (N = 4)
4
5
6
Mean + SEM
9.04 0.09 10.40 + 0.17
(N = 9) (N = 3)
10.07 0.10 10,85 0.09
(N=4) (N=4)
9.22 0.10 10.82 0.11
(N=4) (N=4)
9.49 0.18 10.96 0.16
P<0.OOl
8.76 0.13 11.73 0.36
(N = 11) (N = 4)
10.62 + 0.14 11.77 0.11
(N=4) (N=4)
9.77 0.09 11.32 0.12
(N=4) (N=4)
9.58 + 0.25 11.40 + 0.15
P<0.001
3.12 0.29 2.80
(N = 10) (N = I)
4.12 0.30 3.26
(N=4) (N=4)
4.37 0.07 3.43 + 0.04
(N=4) (N=4)
3.56 0.27 3.07 0.09
P>0.1
5.63 + 0.30 3.62 0.22
(N = 11) (N = 5)
4.29 0.60 2.91 + 0.45
(N=4) (N=4)
4.23 0.09 3.27 0.06
(N=4) (N=4)
3.87 0.52 3.03 + 0.30
P>0.l
Table 4. Values indicated are spontaneous variations of serum iPTH levels expressed in terms ofil Eq/mi in eight control patients on
long-term hemodialysis
.Series N° Patient N°
10 11 12 13 14 15 16 17
1 1900 1200 1350 735 265 350 107 65
2 2200 1175 1412 690 200 270 84 48
3 2000 1312 liii 780 320 267 120 72
4 1650 1420 1089 803 340 392 78 54
5 1815 1175 1538 702 257 280 92 62
6 2110 1270 1490 648 228 310 131 53
Mean 1946 1259 1332 726 268 312 102 59
Max. difference
from mean 294 161 243 78 72 80 29 13
Max. difference,
%from mean 15% 13% 18% 11% 27% 26% 28% 22%
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A significant and inverse relation (v = —0.7 lx +
8.45, r =
—0.56, P < 0.001) was found between the
predialysis calcium concentration and plasma [cal-
cium], i.e., the lower the predialysis plasma calcium
concentration, the higher was the increase in z
plasma [calcium] during hemodialysis runs.
The plasma phosphorus concentration was well
controlled in all patients at the end of the first period.
It was even overdropped in patient 3, whose mean
plasma phosphorus concentration was only 2.52
mg/100 ml. The same remark could be attributed to
patient 1 at the end of period 2 (1.96 mg/i00 ml),
whereas it was insufficiently controlled in patient 4 at
the end of period 2 (5.63 mg/lOU ml). The mean
plasma phosphorus concentration difference (z plasma
[phosphorus]) was occasionally negative, such as in
patient 3 during periods I and 2 (Table 5).
Calcium transfer across the dialysis membrane
(mean SEM) increased from 0.99 0.09 mg/mm
during period ito 1.38 0.16 mg/mm during period
2 (N 4 patients).
Fractional intestinal absorption of calcium in the
postdialysis state is shown in Table 6. In three
patients it was strikingly lower during period 2 when
compared to that of period I, whereas in one patient
(patient 4) it was found slightly increased. For the
four patients studied as a whole, the mean value of
fractional intestinal calcium absorption decreased
from 50 to 35%.
No changes in clinical symptoms or radiological
findings were noted during the two treatment periods.
Serum alkaline phosphatase increased significantly in
patient 2, dropped in patient 5 (in whom it was ini-
tially increased), and remained unchanged in the four
others.
Serum iPTH. Hyperparathyroidism was present in
all six patients (Table 2); serum iPTH levels were
Table 6. Decrease in fractional intestinal absorption of calcium
in three out of four patients during treatment period 2 when
compared to treatment period I
Patient
no.
Fractional intestinal Calcium absorption, %
Period I Period 2
1 42 16
2 60 33
3 56 42
4 40 48
Mean 50 35
extremely high in patients 2 and 5 (1900 and l300d
Eq/mi). In three other cases (patients 1,4, and 6) they
were also high. They were much less elevated in the
last case (patient 3). Increasing the dialysate calcium
concentration did not change significantly these levels
except in one case (patient 2) where it dropped from
1900 to l200il Eq/ml (Table 7). This finding was
reinforced by the results obtained in patients 5 and 6
in whom measurements could be repeated four times
at the end of periods I and 2. It is of interest to note
that such results were obtained after six months as
well as after 8 to 14 months of treatment with an
increased dialysate calcium concentration. The mod-
erate decrease in serum iPTH levels of patients 1, 3, 5,
and 6 during period 2 when compared to period 1 was
in the range of spontaneous variations observed in
"control" patients with repeated determinations over
a short period of time (Table 4). This decrease must
thus be considered as not significant.
Quantitative bone histology. Table 7 shows that the
number of osteoclasts and the active resorption sur-
face decreased only in patient 2, where serum iPTH
dropped. In three other cases (patients 4, 5, and 6),
although serum iPTH did not change significantly,
osteoclastic count and activity increased (for level of
Table 7. Serum iPTH, osteoclast number, and osteoclastic resorption surface
Patient
no.
Dialysate
calcium, mg/IOU ml
Serum iPTH
'ml
Osteoclast count
per mm2 of section
Osteoclastic resorption surface
% of total surface
7.0 8.0 7.0 8.0 7.0 8.0
Normal Oto4O 0.37 + 0.07(sD) 0.59 + 0.l7(sr))
2 l900 1200a 1.65 0.83 4.9 3.37
5 1300b 1105b 2.4 2.8 3.1 3.9
6 960b 895b 1.2 1.9 3.0 3.4
I 776 700 0.39 0.35 2.45 2.1
4 7l0 7l0 0.38 0.54 1.28 2.04
3 340 260k 0.21 0.23 1.45 1.79
Mean + SEM 997.7
221.5
811.7
137.9
NS
1.04 1.11
0.36 0.42
NS
2.70 2.77
0.54 0.36
NS
Mean of two measurements.
bMean of four measurements.
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significance of the latter two, see Table 3). The
changes in serum iPTH, osteoclastic count, and activ-
ity observed at the end of period 2, when compared to
the values obtained at the end of period 1, were not
significant for the group of six patients as a whole.
The details of all bone biopsy data are given in Table
3. Osteocytic osteolysis decreased only in patient 2
associated with the already mentioned decrease in
number of osteoclasts and active resorption surface.
Osteoclastic count and activity increased in three
other cases (patients 4, 5, and 6), either moderately or
markedly; osteocytic osteolysis increased in two of
them (patients 5 and 6; patient 4 was not evaluated).
No change of the latter parameters was observed in
patients 1 and 3. Osteoblastic surface, total osteoid
surface, osteoid volume, and calcification front re-
mained unchanged at the end of period 2 in all
patients.
Discussion
No roentgenologic evidence of soft tissue calcifica-
tion was detected in any patient during either period.
The absence of pathologic calcification visible on x-
ray examination might be due in part to control of
the plasma phosphorus concentration, even if this
control was incomplete in one patient during period
2. The absence of such a control must be considered
extremely hazardous for the patients [17].
The postdialysis total plasma calcium concentra-
tion was moderately increased in four out of six
patients (patients 3 through 6) and for the patients as
a whole during period 2 (Table 5), but this increase
was not statistically significant. The lower the pre-
dialysis plasma calcium concentration, the higher was
the increase of the postdialysis plasma calcium con-
centration. This negative correlation is in agreement
with the finding of an increasing calcium ion transfer
across the dialysis membrane with an increasing cal-
cium gradient [8]. The total calcium transfer during
period 2 was indeed moderately higher than that
during period 1.
The mean postdialysis fractional intestinal absorp-
tion of calcium, which has been studied in four
patients, decreased strikingly in three patients and
increased only moderately in one patient when com-
pared to the postdialysis absorption during period 1.
The mechanism of the decrease in postdialysis in-
testinal calcium absorption during period 2 is un-
clear. It might be related to a higher postdialysis
ionized plasma calcium concentration at the time of
study during period 2 than during period 1 [18].
All patients presented secondary hyperparathy-
roidism, which was extremely severe in two cases
(patients 2 and 5), severe in three others (patients 1,4,
6), and less marked in one (patient 3). Serum iPTH
fell to a significant extent only in one case (patient 2)
during period 2 when compared to period I. Al-
though in three other cases serum iPTH fell also
during period 2, these changes were not considered
significant in the light of the spontaneous variations
of serum iPTH found in control patients (Table 4). A
significant decrease in active bone resorption was
observed in only one patient, while in the remaining
five there was either no change or even a worsening in
osteoclast count, osteoclastic resorption, and os-
teocytic osteolysis during period 2 when compared to
period 1. Osteoclastic bone resorption and pen-
osteocytic osteolysis were initially increased in all
patients in whom they were determined, and the in-
crease in osteoclastic bone resorption was related to
the amount of circulating iPTH for period 1 (r =
0.94, P < 0.001) (see Fig. 1). A similar relationship
was found during period 2 (r = 0.87, P < 0.01) (see
also Fig. 1); it was, however, somewhat different: in
the presence of comparable or even slightly lower
serum iPTH values, higher values for osteoclastic
resorption surface were found.
From these results it is suggested that the increase
in dialysate calcium stimulated the PTH effect both
on osteoclastic proliferation and on resorptive activ-
ity, at least in some patients. These results are in
agreement with previous work [19-21] which has
demonstrated that calcium ions were required to ex-
hibit or potentiate PTH activity.
It was also shown [221 that large amounts of cal-
cium carbonate, given orally to undialyzed uremic
patients exhibiting secondary hyperparathyroidism
300 600 900 1200 1500 1800 2100
Serum iPTH, i Eq/mi
Fig. I. Relationship between serum immunoreactive parathyroid hor-
mone level (iPTH) and active resorption surface during treatment
period I (open circles) and 2 (closed circles). The dotted arrows
indicate the individual evolution of each patient. Period 1: y =
0.002x + 0.502, r = 0.94, P <0.001. Period 2: y = 0.002x + 0.981,
r = 0.87, P < 0.01.
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and osteodystrophy, induced a rise in serum calcium
and increased noticeably the number of osteoclasts.
Thus, as a whole, an increase of the dialysate calcium
to 8.0 mg/l00 ml was not only unable to reduce the
preexisting secondary hyperparathyroidism but even
seemed to potentiate in some cases the activity of the
hormone upon osteoclastic proliferation and activity.
Similar conclusions were reached by other workers in
that increasing the dialysate calcium concentration
alone, to 7.0 [23] and 7.5 mg/100 ml [24], respec-
tively, in the absence of a concomitant treatment by
vitamin D, resulted in no involution of secondary
hyperparathyroidism in hemodialyzed patients. Se-
rum alkaline phosphatase, active osteoblast surface,
and the extent of the calcification front remained
unchanged, whether there was initially evidence of
moderate osteomalacia or not. Again these results are
in agreement with what has been found in untreated
renal osteomalacia [22, 25]. Osteomalacia of renal
failure could not be reversed physiologically by in-
creasing either the dietary calcium or by infusing
calcium. In contrast, the vitamin D derivates [26]
were capable of increasing osteoclastic activity, im-
proving osteoid mineralization, and stimulating bone
formation. More recently, Zingraff et al [27] have
reported that in six dialyzed patients using 1.25 (OH)2
Vit. D3, bone formation and osteoid mineralization
could be stimulated more than bone resorption.
In conclusion, the use of a dialysate calcium con-
centration of 8.0 mg/100 ml did not result in any
advantages over a concentration of 7.0 mg/l00 ml in
five of six patients tested. On the contrary, likely
because serum iPTH levels could not be decreased to
a significant extent, addition of calcium seemed to
stimulate the PTH effects upon osteoclastic resorp-
tion or osteocytic osteolysis, at least in some patients.
Since bone formation and mineralization remained
unchanged, the net skeletal balance, i.e., the net sum
of resorption and formation [19], became less posi-
tive or more negative. In one patient this even led to a
marked decrease in the amount of cancellous bone.
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